These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

197 related items for PubMed ID: 18025375

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region.
    Rzany B, Ascher B, Fratila A, Monheit GD, Talarico S, Sterry W.
    Arch Dermatol; 2006 Mar; 142(3):320-6. PubMed ID: 16549707
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose.
    Monheit G, Carruthers A, Brandt F, Rand R.
    Dermatol Surg; 2007 Jan; 33(1 Spec No.):S51-9. PubMed ID: 17241415
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Botulinum toxins for facial wrinkles: beyond glabellar lines.
    Dayan SH, Maas CS.
    Facial Plast Surg Clin North Am; 2007 Feb; 15(1):41-9, vi. PubMed ID: 17317554
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of a new U.S. Botulinum toxin type A in the retreatment of glabellar lines following open-label treatment.
    Rubin MG, Dover J, Glogau RG, Goldberg DJ, Goldman MP, Schlessinger J.
    J Drugs Dermatol; 2009 May; 8(5):439-44. PubMed ID: 19537366
    [Abstract] [Full Text] [Related]

  • 10. Clostridium botulinum type A toxin for the treatment of upper face animation lines: an Iranian experience.
    Farahvash MR, Arad S.
    J Cosmet Dermatol; 2007 Sep; 6(3):152-8. PubMed ID: 17760691
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study.
    Lagalla G, Millevolte M, Capecci M, Provinciali L, Ceravolo MG.
    Mov Disord; 2006 May; 21(5):704-7. PubMed ID: 16440332
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Beyond Botox.
    Kher U.
    Time; 2003 May 19; 161(20):58-9. PubMed ID: 12776449
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Botox and dentistry--is it worth the risk?
    Thomason R.
    Hawaii Dent J; 2007 May 19; 38(1):19. PubMed ID: 17405504
    [No Abstract] [Full Text] [Related]

  • 19. Effectivity of Dysport in patients with blepharospasm and hemifacial spasm who experienced failure with Botox.
    Badarny S, Susel Z, Honigman S.
    Isr Med Assoc J; 2008 Jul 19; 10(7):520-2. PubMed ID: 18751631
    [Abstract] [Full Text] [Related]

  • 20. Periocular botulinum toxin.
    Flynn TC.
    Clin Dermatol; 2003 Jul 19; 21(6):498-504. PubMed ID: 14759583
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.